Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 12,734 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Male Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)

NCT07364214
View directory record Official record
Conditions
Healthy Participants
Interventions
Quemliclustat
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 21, 2026, 7:36 AM EDT
Completed Phase 3 Interventional

Memokath® 044TW Stent for Treatment of Urethral Stricture

NCT00270504
View directory record Official record
Conditions
Urethral Stricture
Interventions
Memokath stenting
Device
Lead sponsor
Pnn Medical DK
Industry
Eligibility
21 Years and older · Male only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
7
States / cities
San Francisco, California • Jackson, Mississippi • Cleveland, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2009 · Synced Oct 21, 2026, 7:36 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

NCT04557449
View directory record Official record
Conditions
Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
Interventions
PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
14
States / cities
Los Angeles, California • New Haven, Connecticut • Trumbull, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 21, 2026, 7:36 AM EDT
Terminated Phase 2 Interventional

A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.

NCT00179738
View directory record Official record
Conditions
Prostate Cancer
Interventions
CC5013
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
Berkeley, California • Tampa, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2005 · Synced Oct 21, 2026, 7:36 AM EDT
Completed Not applicable Interventional

Physical Activity in Men Newly Diagnosed With Prostate Cancer: A Feasibility Study

NCT03331458
View directory record Official record
Conditions
Prostate Cancer
Interventions
exrecise intervention
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 21, 2026, 7:36 AM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00601926
View directory record Official record
Conditions
Kidney Cancer
Interventions
bevacizumab
Biological
Lead sponsor
Paul Monk
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 21, 2026, 7:36 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis

NCT02138838
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
Cinacalcet HCl, Standard of Care
Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Los Angeles, California • Wilmington, Delaware • Atlanta, Georgia + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 21, 2026, 7:36 AM EDT
Withdrawn No phase listed Observational

Taste And Smell TEsting in End Stage Renal Disease

NCT03043144
View directory record Official record
Conditions
Kidney Failure, Chronic, Olfaction Disorders, Taste Disorders, Malnutrition
Interventions
Worsening of olfaction from enrollment visit to 6 months, Worsening of taste from enrollment visit to 6 months, Serum Zinc, Chronic rhinosinusitis, Dialysis adequacy, Decayed missing filled teeth index (DMFT)
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 21, 2026, 7:36 AM EDT
Completed Phase 2 Interventional

Fulvestrant in Treating Patients With Advanced Prostate Cancer

NCT00244998
View directory record Official record
Conditions
Prostate Cancer
Interventions
fulvestrant
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 21, 2026, 7:36 AM EDT
Recruiting Not applicable Interventional

Double-S: a Wearable Device for Erectile Dysfunction

NCT05451563
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Double-S
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 21, 2026, 7:36 AM EDT
Completed Phase 1 Interventional

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

NCT02406521
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Pazopanib, Sorafenib, Radium-223
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 21, 2026, 7:36 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism

NCT00837616
View directory record Official record
Conditions
Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions
17 B estradiol orally, 17 B estradiol
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 20 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Jacksonville, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 21, 2026, 7:36 AM EDT
Withdrawn Phase 4 Interventional

High Versus Low Bicarbonate Bath in Critically-ill Patients Receiving Continuous Renal Replacement Therapy

NCT03846258
View directory record Official record
Conditions
Metabolic Acidosis, Acute Kidney Injury, Acute Kidney Failure
Interventions
Low bicarbonate solution (22 mmol/L), High Bicarbonate solution (32 mmol/L)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 21, 2026, 7:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

NCT06345755
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407, Placebo, Midazolam
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 21, 2026, 7:36 AM EDT
Recruiting No phase listed Observational

Longitudinal Prospective Natural History Study of Retinopathy in Zellweger Spectrum Disorder

NCT06190626
View directory record Official record
Conditions
Zellweger Spectrum Disorder
Interventions
Not listed
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 21, 2026, 7:36 AM EDT
Recruiting Not applicable Interventional

Feasibility of The Health Integrated Nutrition and Kidney Wellness Program

NCT07518719
View directory record Official record
Conditions
Chronic Kidney Disease, Cardiovascular Disease
Interventions
THINK-Well, Enhanced Usual Care
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
5
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 7:36 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Prophylactic Vs. Therapeutic Use of Uroxatrol in Men Undergoing Brachytherapy

NCT00201630
View directory record Official record
Conditions
Prostate Cancer
Interventions
Uroxatrol (drug)
Drug
Lead sponsor
New York Prostate Institute
Other
Eligibility
0 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Oceanside, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2005 · Synced Oct 21, 2026, 7:36 AM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

NCT04936230
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
83
States / cities
Littleton, Colorado • Bloomington, Illinois • Canton, Illinois + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 21, 2026, 7:36 AM EDT
Completed Not applicable Interventional Results available

Improving Germline Testing in At-Risk Patients With Prostate Cancer

NCT05470036
View directory record Official record
Conditions
Prostate Cancer
Interventions
Educational intervention.
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 21, 2026, 7:36 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

NCT04497844
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Prednisone, Placebo FDC, Placebo AA
Combination Product · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
53
States / cities
Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 7:36 AM EDT
Not listed Phase 2 Interventional

Tesetaxel for Previously Treated Patients With Bladder Cancer

NCT01215877
View directory record Official record
Conditions
Carcinoma, Transitional Cell
Interventions
Tesetaxel
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Oct 21, 2026, 7:36 AM EDT
Active, not recruiting Phase 3 Interventional

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
1,140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
70
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 21, 2026, 7:36 AM EDT
Completed Not applicable Interventional

Erectile Dysfunction Study

NCT00873665
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
aerobic exercise, wait-list control
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2013 · Synced Oct 21, 2026, 7:36 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

NCT01688492
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ipilimumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
3
States / cities
Evanston, Illinois • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 7:36 AM EDT